Zusammenfassung
Die peritoneale Metastasierung stellt noch immer eine große Herausforderung für das interdisziplinäre Management der betroffenen Patienten dar. Nachdem zunächst sehr große Hoffnungen in die Kombination aus zytoreduktiver Chirurgie (CRS) und hypertherme intraperitoneale Chemotherapie (HIPEC) gesetzt wurden, hat sich in einer kürzlich publizierten randomisierten Studie gezeigt, dass der Wert einer HIPEC neu diskutiert werden muss. Evident scheint jedoch zu sein, dass die CRS bei selektierten Patienten von Vorteil ist, sofern diese mit niedriger Morbidität und Mortalität durchgeführt werden kann.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Allen C, Glasziou P, Del Mar C (1999) Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet (London, England) 354(9186):1229–1233. https://www.ncbi.nlm.nih.gov/pubmed/10520630.
Alyami M, Gagniere J, Sgarbura O et al (2017) Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol 43(11):2178–2183. https://doi.org/10.1016/j.ejso.2017.09.010
Andersen HK, Lewis SJ, Thomas S (2006) Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications. Cochrane Database Syst Rev 2006(4):CD004080. doi:https://doi.org/10.1002/14651858.CD004080.pub2
Brandl A, Raue W, Aigner F, Arroyave MC, Pratschke J, Rau B (2018) Safety of extraperitoneal rectal resection and ileorectal or colorectal anastomosis without loop ileostomy in patients with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Color Dis 20(3):61–67. https://doi.org/10.1111/codi.14004
ERAS Society. https://www.erassociety.org.
Franko J, Shi Q, Goldman CD et al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30(3):263–267. https://doi.org/10.1200/JCO.2011.37.1039
Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004a) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292. https://doi.org/10.1200/JCO.2004.10.012
Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN (2004b) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91(6):747–754. https://doi.org/10.1002/bjs.4473
Goere D, Glehen O, Quenet F, et al (2018) Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of develo** colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394). J Clin Oncol 36(15_suppl):3531. doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.3531
Grundmann RT, Meyer F (2013) Geschlechtsspezifische Einflüsse auf Inzidenz, Screening, Behandlung und Ergebnis des kolorektalen Karzinoms. Zentralblatt fur Chir – Zeitschrift fur Allg Visz und Gefasschirurgie 138(4):434–441. doi:https://doi.org/10.1055/s-0033-1350631
Güenaga KF, Matos D, Wille-Jørgensen P (2011) Mechanical bowel preparation for elective colorectal surgery. Cochrane database Syst Rev 2011(9):CD001544. doi:https://doi.org/10.1002/14651858.CD001544.pub4
Guinney J, Dienstmann R, Wang X3 (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21(11):1350–1356. doi: https://doi.org/10.1038/nm.3967 (Epub 2015 Oct 12)
Gustafsson UO, Scott MJ, Schwenk W et al (2012) Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr 31(6):783–800. https://doi.org/10.1016/j.clnu.2012.08.013
Huang C-Q, Min Y, Wang S-Y, et al (2017) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 8(33). doi:https://doi.org/10.18632/oncotarget.17497
Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID (2014) Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol Off J Eur Soc Med Oncol 25(3):651–657. https://doi.org/10.1093/annonc/mdt591
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374. https://www.ncbi.nlm.nih.gov/pubmed/8849962. Zugegriffen: 5. Apr. 2018
Jayakrishnan et al (2014) Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World Journal of Surgical Oncology. Aug 21;12:270. https://doi.org/10.1186/1477-7819-12-270
Jess P, Hansen IO, Gamborg M, Jess T (2013) A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open 3(5):1–7. https://doi.org/10.1055/s-2004-814421
Kawai K, Nozawa H, Hata K et al (2018) Nomogram predicting survival after recurrence in patients with stage I to III colon cancer. Dis Colon Rectum 61(9):1053–1062. https://doi.org/10.1097/DCR.0000000000001167
Kehlet H (1996) Organizing postoperative accelerated recovery programs. Reg Anesth. 21(6 Suppl):149–151. PMID: 8956444
Kurtz F, Struller F, Horvath P et al (2018) Feasibility, safety, and efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroen Res Pract 2018:2743985. https://doi.org/10.1155/2018/2743985
Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, De Hingh IH (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128(11):2717–2725. https://doi.org/10.1002/ijc.25596
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL, https://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom/. Zugegriffen: 10. Febr. 2019
Lewis SJ, Egger M, Sylvester PA, Thomas S (2001) Early enteral feeding versus “nil by mouth” after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ 323(7316):773–776. https://www.ncbi.nlm.nih.gov/pubmed/11588077
Lim DR, Kuk JK, Kim T, Shin EJ (2017) Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection. Med (United States) 96(42):1–7. https://doi.org/10.1097/MD.0000000000008241
Loupakis F, Yang D, Yau L, et al (2015) Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 107(3). doi:https://doi.org/10.1093/jnci/dju427
Maillet M, Glehen O, Lambert J et al (2016) Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol 23(3):863–869. https://doi.org/10.1245/s10434-015-4914-4
Mayanagi S, Kashiwabara K, Honda M et al (2018) Risk factors for peritoneal recurrence in stage II to III colon cancer. Dis Colon Rectum 61(7):803–808. https://doi.org/10.1097/DCR.0000000000001002
Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A (2015) The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 17(9):772–778. https://doi.org/10.1111/codi.12975
Nagata H, Ishihara S, Hata K et al (2017) Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol 24(5):1269–1280. https://doi.org/10.1245/s10434-016-5732-z
Park JS, Huh JW, Park YA et al (2015) Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Med (United States). 94(15):1–6. https://doi.org/10.1097/MD.0000000000000658
Péron J, Mercier F, Tuech J-J et al (2019) The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery 165(2):476–484. https://doi.org/10.1016/j.surg.2018.07.027
Piso P, Nedelcut SD, Rau B et al (2019) Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol 26(1):148–154. https://doi.org/10.1245/s10434-018-6992-6
Quenet F, Elias D, Roca L, et al (2018) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 36(18_suppl):LBA3503-LBA3503. doi:https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503
Robert Koch-Insitut. Krebs in Deutschland für 2013/2014 (2017) Krebs Deutschl 2013/2014. 2017(11):154. doi:https://doi.org/10.17886/rkipubl-2017-007
Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH (2017) Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol 114:53–62. https://doi.org/10.1016/j.critrevonc.2017.03.028
Schwenk W, Spies C, Müller JM (2009). Fast Track in Der Operativen Medizin. Springer, Berlin. doi:https://doi.org/10.1007/978-3-540-39709-0
Segelman J, Granath F, Holm T, MacHado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99(5):699–705. https://doi.org/10.1002/bjs.8679
Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y (2018) Long-Term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 25(1):173–178. https://doi.org/10.1245/s10434-017-6133-7
Shin US, Cho SS, Moon SM et al (2014) Is microsatellite instability really a good prognostic factor of colorectal cancer? Ann Coloproctol 30(1):28–34. https://doi.org/10.3393/ac.2014.30.1.28
Smeenk RM, Verwaal VJ, Zoetmulder FAN (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94(11):1408–1414. https://doi.org/10.1002/bjs.5863
Sommariva A, Zagonel V, Rossi CR (2012) The role of laparoscopy in peritoneal surface malignancies selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 19(12):3737–3744. https://doi.org/10.1245/s10434-012-2465-5
Sugarbaker PH (2016) Improving oncologic outcomes for colorectal cancer at high risk for local-regional recurrence with novel surgical techniques. Expert Rev Gastroenterol Hepatol 10(2):205–213. https://doi.org/10.1586/17474124.2016.1110019
Wilmore DW, Kehlet H (2001). Management of patients in fast track surgery. BMJ 322(7284):473–476. https://www.ncbi.nlm.nih.gov/pubmed/11222424
Zentrum für Krebsregisterdaten im Robert-Koch-Institut (2016) Bericht Zum Krebsgeschehen in Deutschland 2016. Berlin
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Gül-Klein, S., Müller, V., Alberto, M., Brandl, A., Rau, B. (2021). Die Rolle von zytoreduktiver Chirurgie und HIPEC beim Kolonkarzinom. In: Benz, S., Grützmann, R., Stinner, B. (eds) Chirurgie des Kolonkarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60453-3_32
Download citation
DOI: https://doi.org/10.1007/978-3-662-60453-3_32
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-60452-6
Online ISBN: 978-3-662-60453-3
eBook Packages: Medicine (German Language)